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Sirt-1 is deﬁned as a nuclear protein involved in the molecular mechanisms of inﬂam-
mation and neurodegeneration through the de-acetylation of many different substrates
even if experimental data in mouse suggest both its cytoplasmatic presence and nucleo-
cytoplasmic shuttling upon oxidative stress. Since the experimental structure of human
Sirt-1 has not yet been reported, we have modeled its 3D structure, highlighted that it is
composed by four different structural regions: N-terminal region, allosteric site, catalytic
core and C-terminal region, and underlined that the two terminal regions have high intrinsic
disorder propensity and numerous putative phosphorylation sites. Many different papers
report experimental studies related to its functional activators because Sirt-1 is implicated
in various diseases and cancers.The aim of this article is (i) to present interactomic studies
based human Sirt-1 to understand its most important functional relationships in the light
of the gene–protein interactions that control major metabolic pathways and (ii) to show by
dockingstudieshowthisproteinbindssomeactivatormoleculesinordertoevidencestruc-
tural determinants, physico-chemical features and those residues involved in the formation
of complexes.
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INTRODUCTION
Incomplexbiologicalsystemstheprotein–geneinteractionsoper-
ate under protein–protein or gene–gene interaction maps where
they have speciﬁc functional roles (Barabási and Oltvai, 2004). In
this context well-connected hubs are of high functional impor-
tance (Jeong et al., 2001; He and Zhang, 2006). Consequently,
studies based on protein–protein interaction (PPI) networks can
be inferred from centrality statistics of proteins associated with
disease and biological processes associated with genes and pro-
teins. Genes associated with a particular phenotype or function
are not randomly positioned in the PPI network, but tend to
Abbreviations: ADP, adenine diphosphate; AR, androgen receptor; ARNTL, Aryl
hydrocarbonreceptornucleartranslocator-like;BRCA1,Breastcancertype1suscep-
tibility protein; DLD, dihydrolipoamide dehydrogenase; DYNC1H1, dynein, cyto-
plasmic 1, heavy chain 1; EP300, E1A binding protein p300; FOXOs, forkhead box
protein O; HIC1, hypermethylated in cancer 1; HDAC, histone deacetylase; KAT2,
K (lysine) acetyltransferase 2; KRT1, keratin 1; MCF2L2, MCF.2 cell line derived
transforming sequence-like 2; MYOD1, myogenic differentiation 1; NAD, nicoti-
namide adenine dinucleotide; NCOR1, nuclear receptor co-repressor 1; NEDD8,
neural precursor cell expressed, developmentally down-regulated 8; NFkB, nuclear
factor of kappa light polypeptide gene enhancer in B-cells; NUDC, nuclear dis-
tribution gene C homolog; PARP1, poly (ADP-ribose) polymerase 1; PPARGC1A,
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; RELA, V-
rel reticuloendotheliosis viral oncogene homolog A; RPS27L, ribosomal protein
S27-like; RRP8, ribosomal RNA processing 8, methyltransferase, homolog; RTN4,
reticulon 4; SLC25A3, solute carrier family 25 (mitochondrial carrier; phosphate
carrier), member 3; SMAD4, SMAD family member 4; SYNCRIP, synaptotagmin
binding, cytoplasmic RNA interacting protein; TP53, tumor protein 53; WRN,
Werner syndrome, RecQ helicase-like.
exhibithighconnectivity;theymayclustertogetherandcanoccur
in central network locations (Goh et al., 2006; Oti and Brunner,
2006).SevendifferenthomologousproteinscomposeSirtuinfam-
ily, and in particular Sirt-1 exhibits a high degree of structural
disorder as demonstrated in a recent work of our group (Autiero
etal.,2009).Ingeneralithasbeenalreadythattheproteindisorder
plays a crucial role in PPIs and in regulatory processes for under-
standing the phenomenon of interactome (Tompa and Fuxreiter,
2008). Therefore,it is important to focus the attention on Sirtuins
because they are involved in numerous processes and implicated
in different diseases. Importantly the second-degree interaction
maps related to these family present 5786 neighbors with aver-
age number of neighbors equal to 84.22. However some sirtuins
have not yet been well studied and not much information are
known in regard to their interaction with other proteins (data
not shown) in second order interactome. In particular, Sirt-1 is
deﬁned as a nuclear protein even if experimental data suggest
also its cytoplasmatic presence and indicate that it is involved
into nucleo-cytoplasmic shuttling upon oxidative stress (Autiero
et al., 2009). Sirt-1 is a NAD+ dependent histone deacetylates
that play important functional roles in many biological processes
causing various modiﬁcations of histone/protein acetylation sta-
tus by several class I and II histone deacetylase (HDAC) inhibitors
(Kyrylenkoetal.,2003).InliteratureitisreportedthatSirt-1regu-
latesgenesilencing,cellcycle,DNA-damagerepairandlifespan.In
speciﬁcdiseasedconditions,Sirt-1regulatesorinteractswithmany
proteins:TP53,NEDD8,SMAD4,DYNC1H1,TUBULIN,NUDC,
DYNACTIN, HDAC4, POLR2H, and BRCA1. For example, Sirt-1
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interacts with TP53 which is a very short lived protein involved in
the acetylation processes and gene activation as consequent target
(Appella and Anderson, 2001). In fact, the inactivation of HIC1
leads to an up-regulation of Sirt-1 which deacetylates and deacti-
vates TP53. This allows the cells to bypass apoptosis and survive
DNA damage (Chen et al., 2005). It is also known that Sirt-1
is involved in inﬂammatory processes and in neurodegenerative
diseases like Huntington (Pallkes et al.,2008). Moreover,in litera-
ture it is reported that Sirt-1 interacts also with HDAC2,HDAC4,
MEF2,SUMO,and UBIQUITIN and that HDAC4 might function
to integrate sumoylation and deacetylation signals via its interac-
tion with UBC9 and Sirt-1 and that acetylation and sumoylation
occur on the same lysine residue (Zhao et al., 2005). This evi-
dences the reason for which the analysis of the Sirt-1 interactome
isof greatinterestinordertoﬁndtherelationshipsbetweennodes
(i.e.,genes,proteins) and their positions as well as the overall rela-
tionships in the entire system along with structural inferences of
activators associated with it.
Since the 3D structure of Sirt-1 has not yet been obtained
experimentally, we have recently modeled this protein by com-
putational methods and highlighted that it is composed by four
different regions: N-terminal region, allosteric site, catalytic core
and C-terminal region and underlined that the two extended ter-
minal regions of about 250 residues each are highly disordered
(Autiero et al., 2009). Sirt-1 is implicated in numerous diseases
and cancers and many different papers report experimental stud-
ies related to the effects of its activation. In fact, Sirt-1 activation
by natural activators seems to show a wide spectrum of bene-
ﬁcial effects in cardiovascular, metabolic, and neurodegenerative
diseases and, hence, interest is increasing in testing more potent
Sirt-1 activators for the treatment of these aging associated dis-
eases. The natural activator resveratrol has been largely studied
because of its low toxicity in humans and its anti-aging proper-
ties (Orallo, 2006; Harikumar and Agarwal, 2008). In particular,
it is an important constituent of red wine (Zhuang et al., 2003)
that increases the cell survival in several animals by stimulat-
ing the Sirt-1 dependent deacetylation of TP53 (Howitz et al.,
2003). Since natural compounds failed to induce an increased
activity of Sirt-1 (Yang et al., 2007), new activators (SRT1460,
SRT1720, SRT2183) with a good afﬁnity for Sirt-1 have been
synthesized. Recently, a pharmaceutical biotechnology company,
startingfromtheseactivators,discoverednovelselectiveSirt-1acti-
vators using a high-throughput screening methodology (Smith
et al., 2009; Vu et al., 2009; Yamazaki et al., 2009). In this article
we will report studies on the Sirt-1 interactome and on molec-
ular complexes between Sirt-1 and four different activators, i.e.,
SRT1460,SRT1720,SRT2183,and resveratrol,by molecular dock-
ing (Camins et al., 2010). Since the human sirtuin is proving to
be a multifunctional protein with a large spectrum of biological
activities and partners,the analysis of its interactome is an impor-
tantsteptodeﬁnewhichbiologicalprocessisdirectlyorindirectly
controlled by this molecule. This information is preliminary to
understand the structural characteristics of complexes between
sirtuin and those ligands that have been shown to regulate its bio-
logical activity. Starting from this knowledge we can design new
moleculesinatargetedwaytocontrolspeciﬁcbiologicalfunctions
dependent on sirtuin.
MATERIALS AND METHODS
INTERACTOMIC STUDIES
Cytoscape software (Kohl et al., 2011) is used to visualize the net-
work of Sirt-1 family. The experimentally evidenced interactions
of Sirt family proteins were ﬁltered from Bio grid, HPRD, MINT,
and Pathway Interaction Database which are curated from both
high-throughput data sets and individual focused studies along
with interaction published in peer reviewed journals (Watts and
Strogatz, 1998; Stark et al., 2006; Chatr-Aryamontri et al., 2007;
Keshava Prasad et al., 2009; Schaefer et al., 2009). Further more
the manually curated PPI network is obtained from Center for
BioMedical Computing (CBMC) at University of Verona. Cen-
trality statistics of the protein network are vitals for attaining
properties of the network (Assenov et al., 2008; Scardoni et al.,
2009). In particular, we focused most of our attention on central
vertices in complex networks since they might play the role of
organizational hubs. Betweenness centrality (BC; Freeman, 1977;
Joy et al.,2005) and closeness centrality (CC;Wuchty and Stadler,
2003) are based on the calculation of shortest paths. Przulj et al.
showed bottleneck’s importance in protein interaction networks
and their correlation with gene essentiality (Przulj et al., 2004;
Yu et al., 2004). Lin et al. (2008) proposed two characteristic
analysisalgorithms:maximumneighborhoodcomponent(MNC)
anddensityof maximumneighborhoodcomponent(DMNC)for
exploring essential proteins (Hub proteins) from protein interac-
tion networks (Lin et al., 2008). Most of these different methods
for identifying essential nodes from the network have been stated
in literature (Mason and Verwoerd, 2007). We utilized Maximal
Clique Centrality (MCC), MNC, and DMNC, EPC, and other
centrality based measure are taken into account for exploring the
potentialhubsininteractionmapsof Sirt-1.Geneontologicaldata
were mapped to nodes (Proteins) in the network. Gene Ontolog-
ical study of a network infers about biological process, molecular
function, and cellular location of the interactants present in the
interactome.Signiﬁcantclusteringofgenes,mappedwithproteins,
are layered into Graphs of the Gene Ontology and they are iden-
tiﬁed using the GO enrichment analysis plugin BiNGO (Maere
et al.,2005).
MOLECULAR DOCKING STUDIES
Most cellular processes are carried out by PPIs. Predicting the 3D
structures of protein–protein complexes by docking, it can shed
lightontheirfunctionalmechanismsandrolesincell.Dockingcan
assist in predicting PPIs,in understanding signaling pathways and
in evaluating the afﬁnity of complexes (Andrusier et al., 2008).
In this work, docking studies were done both to get structural
models of those Sirt-1 complexes suggested by the interactome
analysis and to understand the structural determinants underly-
ing the interaction of Sirt-1 with small molecules that have the
function of effectors. Automated docking is widely used for mod-
eling biomolecular complexes in structure/function analysis and
in molecular design. There are several effective methods available,
incorporating different parameters such as algorithm and scoring
function to provide reasonably good predictions. AutoDock4 is
resulted a very useful tool for predicting the complexes conforma-
tionandtherelatedbindingenergiesof ligandswithproteins.The
basic algorithm used for conformational searching in AutoDock4
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is Lamarckian genetic algorithm (LGA; Morris et al., 1998). This
algorithm works on the basis of the stepwise generation selec-
tion. In fact, during the docking simulation a test population of
docking conformation is created and in subsequent stepwise gen-
erations these individual conformations are selected for the next
generation and in this way the best conformation is obtained.
LGA has an additional feature called “Lamarckian” that allows to
the individual conformation of searching the local conformation
space, of ﬁnding the local minima and, then, of passing this to
next generation. In particular, AutoDock4 uses a semi empiri-
cal free energy force ﬁeld to predict binding free energy of small
moleculesandmacromolecules,presentsothertraditionalfeatures
such as Simulated Annealing and genetic algorithm and uses a
force ﬁeld that refers to the form and parameters of mathemat-
ical function used to describe the potential energy of a system
of particles and leads to calculate the intermolecular energies for
predicting free energy of binding. AutoDock 4 is composed by
two software packages, i.e.,AutoDock and AutoGrid, and consists
of Rigid Docking and Flexible Docking modules. Rigid Docking
(calledalsoGrid-basedapproach)allowstheligandtohavealarge
andaﬁxedconformationalspacearoundprotein.Inthisapproach
the target macromolecule is embedded in the grid,the interaction
energy between the probe and the target is computed and stored
in this grid and is used as input for docking simulation. In this
case, the relative orientation of molecules interacting with each
other are allowed to change whereas the internal geometry of the
target molecule is kept ﬁxed. On the other hand,Flexible Docking
module includes the side chain ﬂexibility. In fact,in this approach
a speciﬁc part of the target molecule is made ﬂexible and, during
thedockingtime,theseﬂexiblepartsaretreatedexplicitlyallowing
rotations of bond angles around torsion degrees of freedom.
The most important part in docking is the selection of the cor-
rectactivebindingsite.Incertaincasesthebindingsiteareaonthe
surface of the protein is found with the help of speciﬁc software
but the selection is also addressed on the basis of prior knowl-
edge of the protein. Before setting up the docking run, ligands
and receptor or target molecule were prepared by adding charges,
torsions, and hydrogen atoms by speciﬁc tools. This preparation
is important to mimic the“in vivo”conditions of molecular inter-
action (see Figure A1 in Appendix). After the preparation of
parameter and map ﬁles, AutoDock suite was launched for the
process of docking that generates as output a log ﬁle (DLG) con-
taining all the information of docked complexes (see Figure A2
in Appendix). The description of AutoDock procedure used to
simulate the complexes between Sirt-1 and the four activators is
shown in Figure 1. The ﬁrst docking methods or rigid docking
FIGURE 1 |The description of theAutoDock protocol used to simulate the complexes between Sirt-1 and its four activators.
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treated proteins as rigid bodies (means the internal geometry of
themoleculearekeptﬁxed)inordertoreducethesearchspacefor
optimalstructureof complexes(WodakandJanin,1978;Halperin
et al., 2002). However ignoring ﬂexibility could prevent docking
algorithms from recovering native associations (Andrusier et al.,
2008) and specially in the case of unordered proteins or highly
ﬂexible proteins one cannot ignore the importance of ﬂexible
docking. Moreover, ﬂexibility in docking should be taken into
account if docked structures were determined by homology mod-
eling (Marti-Renom et al., 2000) or if loop conformations were
modeled (Soto et al., 2008) and this scenario implies in our case
thepresenceof twounorderedloops/regions,i.e.,N-terminusand
C-terminus (Autiero et al., 2009). The beneﬁt of rigid docking
procedure is relatively low in computational time and is less com-
plex (Andrusier et al., 2008) but we cannot ignore the structural
characteristic of Sirt-1. Therefore we have used this peculiar pro-
tocol that use steps of rigid docking followed by steps of ﬂexible
docking to generate near native models of complexes made with
ﬂexible Sirt-1 protein.
RESULTS
CENTRALITY STATISTICS OF FIRST ORDER INTERACTION OF Sirt-1
Sirt family ﬁrst order interaction maps, obtained concerning
experimental data reported in protein databases (see Methods
section),have228nodesand3769edges(interactions).Theextrac-
tionofﬁrstorderinteractionmapofSirt-1has136nodesand1503
edges with Sirt-1 as a central node of the network (Figure 2). A
statistic analysis of ﬁrst order interaction map of Sirt-1 was per-
formed. In particular, given undirected networks, the clustering
coefﬁcient Cn of a node n is deﬁned as Cn =2en/[kn(kn −1)],
where kn is the number of neighbors of n and en is the num-
ber of connected pairs between all neighbors of n (Barabási and
Oltvai,2004).Indirectednetworks,thedeﬁnitionisslightlydiffer-
ent:Cn =en/[kn(kn −1)].Theevaluationof theaverageclustering
coefﬁcient distribution gives the average of the clustering coefﬁ-
cients for all nodes n with k neighbors and identiﬁes a modular
organization of networks. The clustering coefﬁcient Cn for undi-
rected network of the Sirt-1 interaction map is 0.717. The mean
shortestpathlengthbetweenanytwoproteinsis1.836(Figure3A).
FIGURE 2 | SIRT family interaction maps containing 136 nodes and 1503 edges. Black lines are interactions and nodes (proteins) are represented by Circles.
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FIGURE 3 |Analysis of ﬁrst order interactome for Sirt-1 composed
by 136 nodes and 1504 edges.The shortest path length distribution
(A) indicates that the network possesses small-world property.The
node degree distribution (B) shows a scale free network property. (C)
Average clustering coefﬁcient of Sirt-1 network showing constant
decrease (D) topological coefﬁcient giving insights on the measure of
extent to which a protein in the network shares interaction partners
with other proteins.
Thetop30best-connectednodesobtainedbyaveragepathlength,
as calculated by Centiscape (see Table 1), have relatively lesser
average path length in respect to TP53 Interactome (Dartnell
et al., 2005). The node distribution degree of Sirt-1 interactome
gives information of the protein interactions with the k other
proteins (Figure 3B). In details, it tends to decrease slowly com-
plying with the power law y =axb where “a” is 4.971 and “b”i s
−0.232withacorrelationcoefﬁcientof 0.113.Thisvalueindicates
a scale free network (Barabási and Oltvai, 2004) and in general
these are very robust against failure, such as removal of arbitrary
network elements. This evaluation suggests that the Sirt-1 inter-
action map is assortative and has a low value of vertices. In this
network the average number of interacting partners was evalu-
ated and it resulted equal to 22.10. Moreover, since J e o n ge ta l .
(2001) showed that a protein acting as hub is more important
thanthosesparselyconnectedwithasmallnumberof interactions
(Jeongetal.,2001),wecalculatedtheputativehubproteinspresent
in our network by using different algorithms like MCC, DMNC,
MNC and Edge Percolated component and different centrality
based measures. In Table 2 are reported the top 10 hub proteins
obtained by these analysis but only ﬁve of them (SLC25A3, Sirt-
1, JUN, MCF2L2, and EP300) were selected as hub by all used
different algorithms.
ParametersrelatedtotopologicalaspectsofSirt-1neighborsare
acquired by calculating the average clustering coefﬁcient of pro-
teinsthatshowstendencytoformclustersorgroups(Barabásiand
Oltvai,2004). Sirt-1 network has a constant decrease in clustering
coefﬁcients due to the higher number of interaction of each pro-
tein (Figure 3C). This suggests that it is a small-world network
having hierarchical modularity. Ravasz et al. (2002) showed that
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Table 1 |Top 30 neighbors based on smallest average path length.
Average path length Proteins
1 SIRT-1
1.64 YBX1
1.66 HSP90AB1, HSPA5, EEF1A1
1.68 RPS3
1.69 HDAC2, HSPA1L
1.71 RUVBL2, RPL23, WDR77
1.73 SLC25A6, SLC25A3, DNAJA2
1.74 TP53,XRCC6,TAF9,SYNCRIP ,TRRAP ,SLC25A5
1.76 KAT2A, SLC25A5
1.77 EP300, DYNC1H1, SND1, RPS27L, TADA 3,
SART3, AASDHPPT, EIF2C1, RPL38, DDOST
In particular, Sirt-1 is having the least Avg path length of 1 as it is central node of
the network. Average path length denotes average number of steps along the
shortest paths for all possible pairs of network nodes.
AASDHPT, aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl
transferase; DDOST, dolichyl-diphosphooligosaccharide – protein glycosyltrans-
ferase; DNAJA2, DnaJ (Hsp40) homolog, subfamily A, member 2, DYNC1H1,
dynein, cytoplasmic 1, heavy chain 1; EEF1a1, eukaryotic translation elongation
factor 1 alpha 1; EIF2C1; eukaryotic translation initiation factor 2C, 1; EP300;
E1A binding protein p300; HDAC2, histone deacetylase 2; HSPA1L, heat shock
70kDa protein 1-like; HSPA5, heat shock 70kDa protein 5; HSP90AB1, heat
shock protein 90kDa alpha (cytosolic) class B member 1; KAT2A, K(lysine)
acetyltransferase 2A; RPL38, ribosomal protein L38; RPS27L, Ribosomal
protein S27-like; RPS3, ribosomal protein S3; RUVBL2, RuvB-like 2; RPL23,
ribosomal protein L23; SART1, squamous cell carcinoma antigen recognized by
T cells 3; SLC25A3, solute carrier family 25 (mitochondrial carrier; phosphate
carrier), member 3; SLC25A5, solute carrier family 25 (mitochondrial carrier;
adenine nucleotide translocator), member 5; SLC25A6, solute carrier family 25
(mitochondrial carrier; adenine nucleotide translocator) member 6; SND, staphy-
lococcal nuclease and tudor domain containing 1; SYNCRIP , synaptotagmin
binding, cytoplasmic RNA interacting protein; TADA3, transcriptional adaptor 3;
TAF9, RNA polymerase II; TATA, box binding protein (TBP)-associated factor;
TP53, tumor protein 53; TRRAP , transformation/transcription domain-associated
protein; WDR77 , WD repeat domain 77; XRCC6, X-ray repair complementing
defective repair in Chinese hamster cells 6;YBX1,Y box binding protein 1.
highly connected regions connect sparsely connected nodes. In
facttheyclassiﬁednetworksintotwomodularorganizations:local
clustering and global networks. Local networks are considered to
have functionality similar to biological processes whereas global
connectivity is related to hub proteins present in the network
connecting high-end nodes (higher order communication points
between protein complexes; Han et al., 2004). Sirt-1 network is
showing a tendency to connected global networks.
The decrease of the topological coefﬁcient with the number
of interacting partners gives information regarding interaction of
proteins with common neighbor (Figure 3D). This shows that
hub proteins (except SLC25 protein family) share fewer common
neighbors then sparsely connected nodes and it also proves that
the early inference of modular organization of Sirt-1 network is
correct. A stressed node in the network is Sirt-1 having the high-
est number of distribution degrees (see supplementary material
for details in Table A1 in Appendix). BC has been evaluated as
the amount of trafﬁc that a vertex or edge has to handle in a
network. In Sirt-1 interactome, the number of nodes has a high
degree of BC and this is reported in (see supplementary material
for details in Table A1 in Appendix). It has been shown that high
degreeofconnectivitycorrelateswellwithpleiotropiceffects(Tyler
et al., 2009). This indicates also that the most part of Proteins in
Sirt 1 interactome map are involved in many different biological
processes with different cellular localizations, more precisely AR,
RELA, and SYNCRIP are present in nucleus as well as cytoplasm
whereas SLC25A5 is in inner mitochondrial membrane as well as
cytoplasm. Sirt 1 is found to interact with proteins involved in
numerous pathways like Foxo Signaling, Regulation of Androgen
receptor activity (Table A3 in Appendix).
GENE ONTOLOGICAL STUDIES OF Sirt-1
GO studies on the hub proteins inferred from our analysis suggest
that they are involved in important biological processes related to
gene regulation, Metabolism and proton co-transport (Table A2
in Appendix). In details, SLC25A3 is responsible for the inor-
ganic phosphate transport into the mitochondrial matrix, either
byprotonco-transportorinexchangeforhydroxylions(k,Entrez
Genedescription),whileJUNinteractsdirectlywithspeciﬁctarget
DNA sequences to regulate gene expression. The centrality analy-
sisbasedonhubproteinsshowedSLC25A3,JUN,Sirt-1,RUVBL2,
and MCF2L2 as important proteins of the network. Other Meth-
ods based on MCC, DMNC, MNC, and EPC evidenced the same
proteins as hub nodes along with EP300, YBX1, RPL38, AR, and
Sirt-2.
Genes associated with proteins and found signiﬁcant in the
interactome were analyzed by the BiNGO package in Cytoscape.
Sirt-1 ﬁrst order interacting partners are involved into numerous
biological processes. Sirt-1 interactome is signiﬁcantly involved
Metabolism modulation related processes (Figure 4). Sirt-2 in
chromatin silencing at rDNA, RPS27L, and RTN4 in regulating
anti-apoptotic phenomena.
Certain processes, like chromatin remodeling and modiﬁca-
tion,involve many important proteins of the network like KAT2B,
NCOR1, HDAC6, RRP8, HDAC2, and KAT2A. Moreover, TP53,
Sirt-2,PPARGC1,CPS1,andJUNareresponsiblefortheprocesses
relatedtotheresponsetostarvationwhereastheresponsetostress
is regulated by NCOR1, MYOD1, KRT1, SIRT2, HDAC2, RPS3,
RELA, FOXO1, HDAC6, and other proteins involved in ncRNA
metabolic processes and in negative regulation of signaling path-
ways. In particular, the important processes like DNA binding
activity transcription factor regulation and DNA repair are shown
to have an involvement with proteins like Sirt-1, Sirt-2, TP53,
PPARGC1A,JUN,EP300,HDAC2,HDAC6,KAT2A,Kat2B,RELA,
RB1,WRN, XRCC5, and XRCC6 (FigureA3 in Appendix).
In particular, the sirtuin network shows that Sirt-2, HDAC6,
HDAC2, Sirt-1, PPARGc1A, TRRAP are implicated in histone
modiﬁcation and histone deacetylation whereas SUV39H1 and
DICER1 are involved in gene silencing phenomenon.
The proteins in Sirt 1 interaction maps showed also differ-
ent cellular localization and molecular function (Figure 4 and
Table A4 in Appendix). In details, Sirt family, ARNTL, WRN,
EP300, SYNCRIP, JUN, RPS3 are proteins showing pleiotropicity
inbiologicalaswellasinthecellularlocalizationintheGOanalysis
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Table 2 |The 10 hub proteins present in Sirt-1 ﬁrst order interaction maps obtained by different algorithms and centrality measures.
MCC DMNC MNC EPC Degree Bottleneck Betweenness Stress Closeness
SIRT1 RPL38 RPL38 JUN JUN JUN JUN JUN SLC25A5
YBX1 RELA SIRT-1 SIRT-1 SIRT-1 SIRT-1 SIRT-1 SIRT-1 TADA2B
SIRT2 SLC25A3 SLC25A3 RELA RUVBL2 RUVBL2 RUVBL2 RUVBL2 HSF1
JUN MCF2L2 SIRT2 SLC25A3 SLC25A3 KPNA3 KPNA3 KPNA3 HNF4A
SLC25A13 AR MCF2L2 SIRT2 SIRT2 MCF2L2 MCF2L2 MCF2L2 TADA3
RUVbl2 SIRT6 AR RPS3 MCF2L2 CNOT10 CNOT10 CNOT10 HIST1H2BC
EP300 SYNCRIP SIRT6 SIRT6 DYNC1H1 WRN WRN WRN EIF2C1
HDAC2 EP300 SYNCRIP EP300 SLC25A13 RPS27L RPS27L RPS27L CMYA5
SIRT6 YBX1 EP300 YBX1 YBX1 SIRT4 SIRT4 SIRT4 NAT10
SLC25A3 HDAC2 YBX1 SIRT3 HDAC2 HDAC2 HDAC2 HDAC2 ARNTL
AR, androgen receptor; CMYA, cardiomyopathy associated 5; CNOT10, CCR4-not transcription complex subunit 10; DMNC, density of maximum neighborhood com-
ponent; EIF2C1, eukaryotic translation initiation factor 2C, 1; EPC, edge percolated component; HIST1H2BC, histone cluster 1, H2bc 2; HNF4A, hepatocyte nuclear
factor 4 alpha; HSF1, heat shock transcription factor; KPNA3, karyopherin alpha 3 (importin alpha 4); MCC, Maximal Clique Centrality; MCF2L2, MCF .2 cell line derived
transforming sequence-like; MNC, Maximum Neighborhood Component; NAT10, N-acetyltransferase 10; RELA, V-rel reticuloendotheliosis viral oncogene homolog
A; RPS27L, ribosomal protein S27-like, RecQ helicase-like;TADA2b, transcriptional adaptor 2B, ribosomal protein L38;TADA3, transcriptional adaptor 3;WRN,Werner
syndrome.
FIGURE 4 |The signiﬁcant GO ontological data related to molecular function with the GO nodes are listed in circles connected by black arrows to the
GO nodes.These yellow and orange color nodes correspond to the statistically signiﬁcant nodes.
maps.Infact,Sirt-1interactswithcytoplasmic,nuclear,extracellu-
larandmitochondrialproteinsasfoundwithasigniﬁcantp value,
i.e., p <0.05 to p >0.0000005 that measures the statistical signif-
icance of the different essentialities of proteins implicated in the
biological processes. RELA and JUN show interactions with mito-
chondrial proteins, Sirt-1 interacts with other cellular proteins in
activating DNA repair and stress protection mechanisms.
SECOND ORDER INTERACTION OF Sirt-1
The Sirt-1 second-degree interaction map is composed of 4691
nodes.Thesenodescorrespondtodifferentpartnersinteractingby
221595 edges (Interactions). The second order network of Sirt-1
is scale free and small-world network interacting with numer-
ous proteins implicated in transcription and metabolism related
processes. Sirt 1 has a high degree of interactions in second order
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interaction maps as it is having interactions with high number of
proteinslikePARP1(inhibitsSirtactivity)andNAMPT(regulates
NAD+ levels;Yang et al.,2006).Analyzing centrality statistics and
pattern of rearrangement of interacting nodes in Second order
interactome of Sirt-1 will provide further insights on the variabil-
ity in functionality,cellular localization,and pleiotropicity nature
of the SIRT interaction map.
MOLECULAR DOCKING STUDIES
Dai et al. (2010) suggested that Sirtuin activating compounds
(STACS) interact directly with Sirt-1 activating the deacetylation
through an allosteric mechanism. This mechanism requires the
presenceofanallostericsiteontheprotein;therefore,wehaveused
for modeling the same structural site on which we have recently
found that binds AROS, the allosteric effector of Sirt-1 known as
endogenous activator (Autiero et al., 2009). So we acquired from
the structural model of the complex AROS–SIRT1,obtained after
docking and molecular dynamics, the putative residues of inter-
action (see Table 3). Hence, our docking studies have focused on
the interactions between the allosteric site found on the native
modeled structure of Sirt-1 and STACs like SRT1720, SRT2183,
SRT1460,andresveratrol(FigureA4inAppendix).Thebestdock-
ing results were obtained by implementing ﬂexible docking in
AutoDock4. In particular, the reason for the selection of this site
depends from the fact that many experimental data have sug-
gested that the modulation of the catalytic activity of Sirt-1 is
exertedthroughtheadjustmentimplementedbytheallostericsite.
Recent works also show that the interaction of Sirt-1 with small
effectors has a functional relevance for its activation (Zhao et al.,
2004;Milneetal.,2007;Bemisetal.,2009).However,themodeled
structure of Sirt-1 shows that the allosteric site selected as bind-
ing area for activators is near to N-terminal region predicted as
unordered (Autiero et al., 2009).
We have also focused our attention on the disordered residues
ﬂanking the allosteric site (see Table 3) considering them as ﬂexi-
bleduringtheprocessof docking.Thisstructuralregioniscloseto
the highly disordered N-terminal segment and involved into the
regulation of the enzyme activity (Tanno et al., 2007; Ford et al.,
2008; Sasaki et al.,2008).
Thegrid-basedapproachwasimplementeddeﬁningarigidbox
(of dimension 4.14×19.56×−24.21 Angstroms) on the surface
of the protein and around the residues of the allosteric site (see
Table 3 and Figure A6 in Appendix) to specify the docking area
for the activators. Parametric details of the grid parameters such
as“number of spacing,”“number of grid points,”and“center grid
box”in all three directions are given in FigureA5 in Appendix.
FIGURE 5 | Side view of four activators docked on the active site. All
the four activators are shown in “stick” conﬁrmation with different colors:
SRT1460 in yellow, SRT2183 in blue, resveratrol magenta and SRT1720 in
red).The active site residues are shown in “surface” conﬁrmation whereas
Sirt-1 by cartoon.The active site region with the docked activators is
highlighted in a white box.
Figures 5 and 6 and Figure A7 in Appendix show the best
dockingmodelscomputedforallthefouractivatorsagainstSirt-1.
The complexes present negative values of the binding free energy,
which indicates that the models between Sirt-1 and its activators
are reliable. Their analysis in terms of interaction residues con-
ﬁrmsthatthebindingregionisconservedwiththeinvolvementof
chargedandaromaticresidueswhichsuggestscomplexesstabilized
by electrostatic and stacking interactions. Moreover, the complex
between Sirt-1 and resveratrol resulted not so stable in respect to
thecomplexesof theotherthreeligands.Thiscanbeinferredfrom
Table 3 | Sirt-1 residues resulted at the interaction interface withAROS (Autiero et al., 2009) and used during the docking studies.
Sirt-1 residues interacting with AROS MET1; ALA2; ASP3; LEU7; GLU161; ASP166; SER169; HIS170;ALA171; SER172; SER173; SER174;
ASP175;TRP176; PRO184;TYR185; PHE187;VAL188; HIS191; LEU192; ILE194; GLY195; THR196;
ASP197;THR219;TRP221; GLN222; ILE223;TRP624; ARG627VAL628
Sirt-1 residues of the allosteric site considered
ﬂexible during the docking studies
HIS170;ALA171; SER172; SER173; SER174;ASP175;TRP176; PRO184;TYR185; PHE187;VAL188;
HIS191; LEU192
Residues common in the interaction surface are indicated in bold.The smaller number of residues involved in the interaction is due to the different molecular sizes
of AROS and small activators.
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the absence of H-bonds and relatively lesser number of charged
interaction residues (Table 4). However, the EC1.5 values related
to the Sirt-1 activity, and reported in the literature, supports the
observation that the resveratrol is a less potent activator (Milne
et al., 2007; Bemis et al., 2009). A remarkable observation that
supports our models is that the experimental EC1.5 values are lin-
earlycorrelatedwiththebindingenergyvaluesfoundbyAutoDock
for the Sirt-1 complexes with the four activators. In fact,a correla-
tioncoefﬁcientof 0.73demonstratesthegoodagreementbetween
functional data and computational results.
DISCUSSION
Human Sirt-1 is an unordered protein (IDP) and may there-
fore adopt types of order (and conformations) that are not easily
FIGURE 6 | Interaction regions in four complexes. All the four activators
are shown in the line/bond conformation with different colors and the
residues (reported inTable 4), which are interacting with their respective
activators, are shown in the CPK conformation.
recognized by current secondary or tertiary structure prediction
algorithm,which primarily recognize higher order assemblies sta-
bleinthetime.Eventheclassicexperimentalstructuraltechniques
oftenfailinstudyingstructuralaspectsof theseproteins.Sirt-1isa
Hubproteinbecauseofitsnumerouspartnersandforitsstructural
characteristic. Structural features that affect the ability of hubs in
PPI networks to recognize and bind multiple partners are numer-
ous. In this article we primarily focused on the role of intrinsic
disorder in the Sirt-1 structure. However, a study in progress in
our laboratory focuses on the charged residues on the surfaces of
thisproteinandontheroleof phosphorylations.Preliminarydata
supporttheideathatithashighlychargedsurfacesascomparedto
large,disordercontaininghubsindicatingitspossibleinvolvement
in promiscuous binding (Patil and Nakamura,2006).
Ourinteractomicanalysisshowedfortheﬁrsttimehowmuchis
vastthenumberof physiologicalpartnersof thishubprotein.Sirt-
1isaninterestingcasebecausewearejustbeginningtounderstand
someof themechanismsthatleadtomulti-speciﬁcityinthebind-
ing of hub proteins. In particular, a huge number of articles have
been published on the clinical, biological and, functional aspects
of human sirtuins but we know only general details about their
structuresandmolecularmechanismswhichgovernthefunctional
behavior of these proteins.
The aim of this study was to evaluate and integrate functional
and structural features by computational methods to predict the
involvement of the human Sirt-1, the most studied of sirtuins,
intothebasicmolecularmechanismdescribingthecomplexregu-
lation of this protein. Since in vitro or in vivo experiments is time
consuming and expensive; in silico prediction can provide func-
tional candidates and help narrow down the experimental efforts.
Moreover, we have also analyzed multiple large-scale experimen-
tal data sets describing the metabolic involvement of the Sirt-1 to
understand the basic mechanism underlying the function of this
hub protein. We have examined objective criteria that could infer
organizations of the Sirt-1 network and the structural determi-
nantsfeaturingtheinteractionbetweenSirt-1andsomebiological
activators which are reported in the literature as potent modula-
tors of the metabolic activities of sirtuin 1 (Milne et al.,2007; Dai
et al.,2010).At the same time,we can make suggestions about the
structural mechanisms underlying the interaction of small mol-
ecule activators on which there is currently much disagreement
(Pacholec et al., 2010). This knowledge may also be used to direct
the design of new and more speciﬁc sirtuin activators.
Table 4 | Interaction details of four complexes compared to experimental data reported in literature.
Name of
activators
Number of
interacting
residues
Name of interacting residues Number and
residue name
of H-bond
Energy
score
(Kcal/mol)
EC1.5
value
SRT1460 13 D166,R 1 6 7 , S169, H170, A171, S172, S173, S174, D175,
W176, P184,Y185, V188
1 H-BOND (S173) −5.62 0.36
SRT1720 9 D163, D166, S172, S173, S174, D175,W176, P177 ,Y185 1 H-BOND (D175) −4.98 0.16
SRT2183 10 D166, R167 , H170, A171, S172, S173, S174, D175,Y185, V188 1 H-BOND (S173) −2.18 2.9
RESVERATROL 8 S173, S174,W176, P180, R181, P184,Y185, V188 NO H-BOND −1.48 36.2
The charged residues are underlined but those aromatic are shown in bold.
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Sirt-1interactomicstudyholdsthekeyforunderstandingasso-
ciations and interactions between various proteins to develop
knowledgeable insights of highly diverse and complex biologi-
cal systems, which are interwoven into each other. On the basis
of the experimental data (see Materials and Methods) at disposal
on various public databases, we have performed an interactomic
analysis and found 136 direct partners interacting with Sirt-1 that
are involved in the important pathways discussed above. Several
proteins are biologically active in metabolic processes whereas
several others proteins perform gene regulatory functions. Scale
freeness of the Sirt-1 interaction map is exhibited by a trend
shown by many proteins with logarithmically decreased connec-
tivity and Sirt-1 interactome shows small-world property with
smaller diameter and high connectivity (Figure 3). These proper-
ties make a network more robust to perturbations like mutations
and viral infections. However, these parameters imply that the
pleiotropicity nature or the complex associations of the proteins
governing different biological processes are found implicated in
many pathways. In particular, some proteins that connect more
nodes in different pathways are, for example, the hub nodes like
JUN, HDAC2, RELA, and SLC25A3. Promislow (2004) showed
that the pleiotropicity is linked to higher connectivity of nodes,
especially, in senescence. However, there is a signiﬁcant amount
of inferences on possible associations between Sirt-1 and caloric
restriction and senescence. Probably, we could suggest that the
pleiotropic nature of the proteins interacting with Sirt-1 may
address the senescence through the involvement of multiple fac-
tors possibly related to stress and mitochondrial proteins or the
processes associated with mitochondria. This derives from the
fact that with aging there is the progression of many diseases
like Parkinson, Huntington and Alzheimer that depend on mito-
chondrial dysfunction. In Sirt-1 interactome the mitochondrial
sirtuins,i.e.,Sirt-3,Sirt-4,and Sirt-5,interact with proteins impli-
cated in different metabolic processes (Figure A8 in Appendix)
and the deregulation of these proteins by any factor can lead
to chronic metabolic disorders. Moreover, the direct interaction
provides some insights about the involvement of Sirt-1 in can-
cer as this protein is also found to be acetylating TP53. In our
studies of the Sirt-1 interactome, this protein and some hub pro-
teins like JUN, RELA, and EP300 show to have interactions with
many different proteins involved in some processes and in dif-
ferent cellular localizations. Further, Sirt-1 interaction map or
other protein interaction networks often demonstrate static pic-
ture of bulk amount of complex dynamic interactions. To get
perspective on modulation of Sirt-1, there will be necessary stud-
ies on dynamics interactions considering the interaction levels in
strength,chronologyinPPImapsandrateorderreactionincaseof
metabolicprocesses.Itwouldbeveryinterestingtoknowtheafﬁn-
ity values for the NAD moiety in Sirt family and PARP’s (second
order interacting partner) of human Sirt-1 (Kolthur-Seetharam
et al., 2006; Bai et al., 2011). Sirt-1 network analysis conﬁned
with GO studies showed agreement to the observations of Bai
et al. (2011). Moreover, Sirtuin genes are found to be controlling
the organism’s health in the times of adversity like in diseased
conditions. CR is one of the phenomenon’s that switch on the
Sirt-1genesforregulatoryfunctionalityandcontrollingthemeta-
bolic pathways. Therefore, hyper activation of the sirtuin genes
might be one of the possible contributory causes for healthier
life.
Since Sirt-1 became an interesting and promising target for its
importanceinlifespanandforitsroleinvariousdiseases(Camins
et al., 2010), the exploration of its pharmacological aspects has
been the topic of key research in last decade. In particular, the
attention has been focused on the role of certain small activa-
tor molecules that affect the activity of Sirt-1. In literature there
are some articles on the interaction between Sirt-1 and activators
(Milne et al., 2007; Dai et al., 2010; Huber et al., 2010; Pacholec
et al., 2010). In particular, Milne et al. (2007) showed that three
syntheticactivators,namelySRT1460,SRT1720,andSRT2183,are
Sirt-1activatorsbetterthanthenaturalresveratrolbecauseECval-
ues of these three synthetic activators are lower than the natural
ones.Moreover,thesecompoundswerereportedtobindtheSirt-1
enzyme – peptide substrate complex at an allosteric site. There-
fore, these Authors suggested the possibility of developing a new
therapeutic approach using both caloric restriction and the direct
activation of Sirt-1 using these activators. In 2010, in contrast to
Milne et al. (2007), other Authors (Huber et al., 2010; Pacholec
et al., 2010) have evaluated the same Sirt-1 activators (SRT1460,
SRT1720, SRT2183, and resveratrol) by employing biochemical
assays containing native substrates such as the p53-derived pep-
tide lacking the ﬂuorophore as well as puriﬁed full-length protein
p53 or acetyl-CoA synthetase 1. In these experiments the four
activators did not lead to apparent activation of Sirt-1 with native
peptide or full-length protein substrates, whereas they activated
Sirt-1 with peptide substrate containing a covalently attached ﬂu-
orophore. In particular,Huber et al. (2010) showed that SRT1720
and SRT2183 effectively decreased acetylated p53 in cells treated
with DNA damaging agents but did so in cells that lack Sirt-1.
Also Pacholec et al. (2010) evidenced that SRT1720, SRT2183,
SRT1460, and resveratrol exhibited multiple off-target activities
againstreceptors,enzymes,transporters,andionchannels.There-
fore, they concluded that these four molecules were not direct
activators of Sirt-1 and required a ﬂuorophore (named TAMRA)
for activating Sirt-1 (Pacholec et al., 2010). Recently, in contrast
to Pacholec et al. (2010) and Huber et al. (2010) but in agree-
mentwithMilneetal.(2007),Daietal.(2010)havedemonstrated
that there are many Sirtuin activating compounds (STACs) that
produce biological effects consistent with direct Sirt-1 activation.
In this study they evaluated again the three STACs (SRT1720,
SRT2183, and SRT1460) and showed that they can accelerate the
Sirt-1 catalyzed deacetylation of speciﬁc unlabeled peptides com-
posed only of natural amino acids in contrast with those Authors
which stated that ﬂuorophores were required for Sirt-1 deacetyla-
tion. Therefore,they suggested that these three molecules interact
directly with Sirt-1 and activate Sirt-1-catalyzed deacetylation
through an allosteric mechanism demonstrating that the com-
plex between STACs and speciﬁc ﬂuorophores was not necessary
for SIRT1 activation (Dai et al., 2010). As one can see the con-
troversy essentially arises because of the lack of details on both
structuralandfunctionalactivityof Sirt-1.Moreover,inouropin-
ion,authorsdonottakeintoaccountthatdisorderedregionsallow
bindingtomultiplepartnersmodulatingtheirfunction.Toachieve
this capacity, these regions are able to interact with numerous
andvariousenzymesthatoperatepost-translationalmodiﬁcations
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of which the kinases are certainly the most studied. They phos-
phorylate sites that are found almost always in disordered zones
modifyinginthiswayboththeabilitytointeractthatthefunction.
Therefore, the presence of speciﬁc kinases in the various cellular
districts, where intrinsically disordered proteins have to be post-
translationally modiﬁed, is fundamental for the activity of these
proteins. In other words, if Sirt-1 with its long disordered termi-
nal arms is controlled by its phosphorylation state (Autiero et al.,
2009), its activity for the recognition of protein partners at any
one time will be directly dependent on the activity of the kinases
andphosphatasesthatactonitinaspeciﬁccellulardistrict.Inthis
regard, it is worth of note that we have found more than 90 puta-
tive sites on the human Sirt-1 arms speciﬁc for about 40 different
humankinases(manuscriptinpreparation).Alltheabovesuggests
thatinvitrotestingofoneoftheseproteinsshouldhaveintheassay
also the kinase necessary for the speciﬁc recognition of partners
or, at least, a sirtuin already post-translationally modiﬁed for the
speciﬁc substrate. Only reasoning on this basis it will be possi-
ble to properly test and compare the functional activity of these
proteins. However, often the experimentalists act with the tradi-
tional structure centric view characteristic of globular enzymes
that cannot be applied to IDPs because their activity in respect of
asubstrateisstronglydependentonthosepost-translationalmod-
iﬁcations required to correctly recognize that substrate. It seems
evident that a computational approach in these cases is useful for
understanding and directing studies in solution. This has led to
the lack of conclusive data particularly on small molecule activa-
tors due to the not easy comparability of the results of in vitro
and in vivo experiments. We think that the ﬁeld has been over-
focused mainly with functional studies performed without taking
account at structural level of the different structural behavior of
the intrinsically disordered proteins and of the necessary recog-
nition speciﬁcity determined by the presence of the numerous
kinases.Moreover,conﬂictsatphysiologicallevelareprobablydue
to animal models that are not genetically appropriate. The issue
of longevity is extremely complicated because the aging involves
many genes and the small molecules like polyphenols have gained
attention because they can enter cellular machinery and exert epi-
genetic changes in hundreds of genes; therefore, higher standards
for genetic analysis are required and it is important to assess if
the longevity is due to a direct binding to Sirt-1 or to other phys-
iological effects sirtuin independent. Therefore, in this work we
have modeled by ﬂexible docking studies the complexes between
Sirt-1 and the four activators (SRT1460, SRT1720, SRT2183, and
resveratrol)reportedbyMilneetal.(2007).Giventhatwerecently
modeled the interaction between AROS and the allosteric site of
Sirt-1(Autieroetal.,2009),Milneetal.(2007)andDaietal.(2010)
showed that these molecules can interact directly with Sirt-1 and
activate it through an allosteric mechanism, therefore, we have
decidedtosimulatetheseinteractions.Inparticular,ﬂexibledock-
ing study was chosen because of the highly ﬂexible and unordered
natureof Sirt-1protein,thatiscomposedof fourdifferentregions
(Autiero et al., 2009), of which the two terminal domains are
resulted highly unordered. In particular, the area selected for
binding of these activators is a ﬂexible loop joining N-terminal
and allosteric site. In this particular scenario it is important to
concern ﬂexible binding area, as it will add more authenticity
to the docking results. In fact, ﬂexible docking environment can
mimic the “in vivo” conditions of molecular interaction such as
change in certain bond angles or bond lengths take place when
two molecules tend to interact. In this work 13 residues present
in the allosteric site were chosen to be ﬂexible. In details, these
13 residues selected from the selective binding site area com-
prise four hydrophilic (SER172, SER173, SER174, TYR185), three
hydrophobic (ALA171,VAL188,LEU192),one negatively charged
(ASP175),twopositivelycharged(HIS170,HIS191),andthreearo-
matic residues. The signiﬁcance of aromatic residues and charged
residuesintheareaof activesiteisveryimportantbecausetheyare
involvedinputativestackingandelectrostaticinteractions,respec-
tively. Moreover our results evidence that aromatic residues form
H-bondsthatisimportantforthestructuralcompactnessandsta-
bility of the docked complexes. The comparison between ﬂexible
docking results and the experimental data indicates that the well
known natural activator, resveratrol, does not show good binding
afﬁnity for Sirt-1 respect to other synthetic activators (SRT1460,
SRT1720, SRT2183). In fact, resveratrol has lower afﬁnity than its
synthetic counterparts as shown from binding free energy values
(expressed in Kcal/mol) and the lack of H-Bond formation with
Sirt-1. Figure A9 in Appendix shows the correlation between the
energy values found for the four tested small molecules and the
values of EC,experimentally determined (see Table 4).As one can
see, while for synthetic molecules there is a correlation coefﬁcient
of 0.97 which indicates a good agreement between our structural
data of direct binding and physiological data, the resveratrol is
the only molecule that does not correlate with the others due to
its poor correlation coefﬁcient. This suggests that the biological
activity does not depend on a direct binding. Thus, our docking
modelresveratrol–sirtuin-1clearlyshowsthatresveratrolisapoor
allosteric modulator. Its binding energy is lower than that of the
other modulators (see Table 4).
On the basis of these results we can highlight that the use of a
ﬂexible docking in the case of intrinsically unordered and highly
ﬂexible proteins such as Sirt-1 is able to successfully simulate pro-
tein complexes since our docking data are in agreement with the
functional data. This is the ﬁrst example,to our knowledge,that a
docking between a ﬂexible and disordered protein and ligands is
not only able to simulate the experimental data but also to clearly
discriminate between different hypothesis. However recently it
has also been reported that ligand-receptor docking studies of
CXCR4 (Kufareva et al., 2011) failed to correctly predict the lig-
and binding sites despite the availability of template GPCR crystal
structures.WeobservethatintheX-raystructureofCXCR4(PDB:
3ODU)ismissingtheN-terminusof about50residues.Thispoint
as we will discuss later is important. Each chemokine receptor
has an extracellular N-terminal region, seven helical transmem-
brane domains with three intracellular and three extracellular
hydrophilic loops, and an intracellular C-terminal region. The
ﬁrstandsecondextracellularloopsarelinkedtogetherbydisulﬁde
bondingbetweentwoconservedcysteineresidues.TheN-terminal
regionofachemokinereceptorisstructurallyimportantbecauseit
iscrucialforligandspeciﬁcitywhereastheintracellularC-terminal
region couples G-proteins and this mechanism is implicated for
receptor signaling transduction. In a study in progress in our lab
(manuscript in preparation) we have found diffuse presence of
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disorder in the family of the human chemokine membrane recep-
tors. N and C terminal arms possess structural characteristics
such that they can be considered intrinsically disordered with a
high structural ﬂexibility and the presence of numerous charged
patches and phosphorylation sites. Without any consideration of
these important structural aspects of CXCR4 (not resolved by X-
ray),wethinkthatdockingsfailedbecauseevidentlythestructural
features of N-terminus play a crucial role in the binding of those
ligands and most of all the ﬂexibility also plays a structural role
which must carefully taken into account in docking as we have
done with Sirt-1.
To better validate our docking results, we have compared
the complexes between Sirt-1 and the four activators (SRT1460,
SRT1720, SRT2183, and resveratrol) obtained by AutoDock4, a
very useful tool for predicting the complexes conformation (Mor-
ris et al., 1998, 2009), with those performed by Glide, a program
thatusesadifferentprotocolindicatedas“ﬂexible”(Halgrenetal.,
2004).Thebestcomplexesgeneratedbythislastprograminterms
of energetic values showed that (i) the four molecules bind the
same allosteric site predicted forAROS with good afﬁnity and use
about 90% of interactions evidenced by AutoDock4 but with the
same number and type of H-bonds and (ii) the correlation coefﬁ-
cient between energy score by AutoDock4 and Glide programs is
0.91 (FigureA9 in Appendix).
These results have evidenced the good accuracy of our com-
plexes between Sirt-1 and four molecules even if the certainty of
the result can be obtained only by experimental studies. Hence,
further studies will be performed to validate experimentally our
computational results by biochemistry assays.
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APPENDIX
FIGUREA1 | Description of the usage ofAutoGrid Suite in the
AutoDock4 software package, that generates map ﬁles specifying the
area over the surface of protein for ligand binding on the basis of
information provided in GPF ﬁles, i.e., Grid Parameter ﬁle.
FIGUREA2 | Description of the usage ofAutoDock Suite in the
AutoDock4 software package, that generates the ﬁnal docking log ﬁle
containing information about the ﬁnal docked complex.
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FIGUREA3 | Nodes in magenta represents the proteins involved in DNA bindingActivity whereas proteins involved inTranscription regulating activity
in GO studies are represented in purple.
FIGUREA4 | Chemical structures of four activators which are used in
molecular docking studies against Sirt-1 (Pacholec et al., 2010).
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FIGUREA5 | Details of the grid parameters such as “number of spacing,” “number of grid points,” and “center grid box,” in all three directions.
FIGUREA6 | Representation of the grid box created on the surface of
Sirt-1 around the allosteric site. In details, Sirt-1 is reported in yellow
cartoon conformation and the area of active site in the cpk conformation.
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FIGUREA7 | Different view of active site (represented in the surface conformation by Pymol) of four directions. Concerning a clockwise direction, the
ﬁrst view shows the front view (A), the second shows the top view (B), the third shows the side view (C), and the fourth shows the rear side view of active
site residues (D).
FIGUREA8 |Yellow colored nodes are showing the interaction of mitochondrial sirtuins (Sirt-2, Sirt-3 and Sirt-4).
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A A
B
FIGUREA9 | Correlation between energy scores byAutoDock4 and the values of EC1.5, experimentally determined (A) between energy scores by
AutoDock4 and Glide programs (B).
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TableA1 |The interacting partners and the centrality values associated with Sirt1 direct interacting partners.
ID Eccentricity Radiality Node degree Stress Closeness betweenness Centroid
HIST1H4F 0.5 1.007407407 1 0 0.003717472 0 −134
DIAPH3 0.5 1.155555556 21 0 0.004016064 0 −114
CTTN 0.5 1.192592593 26 260 0.004098361 61.65401265 −109
USP22 0.5 1.2 27 0 0.004115226 0 −108
YBX1 0.5 1.355555556 48 1150 0.004504505 236.8117886 −87
HSF1 0.5 1.051851852 7 20 0.003802281 3.261976912 −128
PER2 0.5 1.022222222 3 0 0.003745318 0 −132
ATG7 0.5 1.044444444 6 14 0.003787879 4.981818182 −129
USP9Y 0.5 1.162962963 22 30 0.004032258 3.382936508 −113
RLN3 0.5 1.007407407 1 0 0.003717472 0 −134
CITED4 0.5 1.014814815 2 0 0.003731343 0 −133
HNRNPUL1 0.5 1.207407407 28 44 0.004132231 5.115295815 −107
HOXB1 0.5 1.014814815 2 0 0.003731343 0 −133
NUDT21 0.5 1.02962963 4 2 0.003759398 0.4 −131
C1QBP 0.5 1.155555556 21 90 0.004016064 15.56143024 −114
ATP1A1 0.5 1.2 27 0 0.004115226 0 −108
HDAC2 0.5 1.303703704 41 880 0.004366812 241.4581972 −94
JUN 0.5 1.155555556 21 244 0.004016064 60.87072927 −114
ZBTB7A 0.5 1.051851852 7 14 0.003802281 2.370707071 −128
E2F1 0.5 1.081481481 11 44 0.003861004 7 .796897547 −124
TADA3 0.5 1.22962963 31 186 0.0041841 46.44718615 −104
POFUT2 0.5 1.2 27 0 0.004115226 0 −108
NR1H2 0.5 1.037037037 5 6 0.003773585 1.233333333 −130
SIRT5 0.5 1.051851852 7 8 0.003802281 1.752380952 −128
GSK3B 0.5 1.140740741 19 212 0.003984064 51.19381729 −116
SIRT2 0.5 1.111111111 15 146 0.003921569 58.07142857 −120
CCDC101 0.5 1.207407407 28 34 0.004132231 3.075757576 −107
HES1 0.5 1.014814815 2 0 0.003731343 0 −133
SIRT3 0.5 1.088888889 12 70 0.003875969 23.90622711 −123
SYNCRIP 0.5 1.259259259 35 444 0.004255319 70.4048396 −100
PAPOLA 0.5 1.037037037 5 8 0.003773585 1.819047619 −130
DNAJA2 0.5 1.266666667 36 324 0.004273504 34.0688319 −99
HSPA1L 0.5 1.303703704 41 756 0.004366812 129.3411642 −94
CLOCK 0.5 1.051851852 7 18 0.003802281 6.071428571 −128
HSP90AB1 0.5 1.340740741 46 910 0.004464286 139.8057991 −89
ARHGAP29 0.5 1.155555556 21 0 0.004016064 0 −114
NAT10 0.5 1.155555556 21 0 0.004016064 0 −114
TMEM33 0.5 1.207407407 28 20 0.004132231 1.061319967 −107
CHCHD2 0.5 1.155555556 21 0 0.004016064 0 −114
TRRAP 0.5 1.251851852 34 364 0.004237288 122.354329 −101
DOT1L 0.5 1.007407407 1 0 0.003717472 0 −134
ELL3 0.5 1.155555556 21 0 0.004016064 0 −114
FHL2 0.5 1.118518519 16 110 0.003937008 27 .81993562 −119
KLHL23 0.5 1.2 27 0 0.004115226 0 −108
HEY2 0.5 1.022222222 3 2 0.003745318 1 −132
SIRT7 0.5 1.044444444 6 0 0.003787879 0 −129
AASDHPPT 0.5 1.222222222 30 156 0.004166667 65.43333333 −105
AR 0.5 1.148148148 20 218 0.004 49.62665945 −115
FAM48A 0.5 1.207407407 28 50 0.004132231 14.68571429 −107
MYOD1 0.5 1.088888889 12 76 0.003875969 17 .44062049 −123
NEDD8 0.5 1.044444444 6 12 0.003787879 4.244444444 −129
(Continued)
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TableA1 | Continued
ID Eccentricity Radiality Node degree Stress Closeness betweenness Centroid
HIC1 0.5 1.007407407 1 0 0.003717472 0 −134
WDR77 0.5 1.281481481 38 372 0.004310345 34.81392157 −97
ATXN7L3B 0.5 1.2 27 0 0.004115226 0 −108
RPL23 0.5 1.288888889 39 468 0.004329004 53.71204567 −96
USP27X 0.5 1.2 27 0 0.004115226 0 −108
NR1H3 0.5 1.02962963 4 6 0.003759398 1.4 −131
CNOT10 0.5 1.2 27 0 0.004115226 0 −108
HIST1H2BC 0.5 1.2 27 174 0.004115226 22.27959818 −108
EP300 0.5 1.222222222 30 666 0.004166667 228.5605339 −105
RPS27L 0.5 1.22962963 31 116 0.0041841 11.38406389 −104
DEDD 0.5 1.2 27 0 0.004115226 0 −108
EIF2C1 0.5 1.222222222 30 90 0.004166667 7 .877714563 −105
RPS3 0.5 1.318518519 43 708 0.004405286 93.02002658 −92
PPARGC1A 0.5 1.051851852 7 24 0.003802281 5.652380952 −128
SND1 0.5 1.22962963 31 208 0.0041841 93.26666667 −104
CMYA5 0.5 1.162962963 22 34 0.004032258 6.219047619 −113
SART3 0.5 1.222222222 30 98 0.004166667 15.94178383 −105
SIRT1 1 2 135 15352 0.007407407 10940.83505 81
HSPD1 0.5 1.4 54 1384 0.00462963 242.3024192 −81
TAF5L 0.5 1.207407407 28 34 0.004132231 3.075757576 −107
NCOR2 0.5 1.111111111 15 120 0.003921569 32.02236652 −120
SSR1 0.5 1.2 27 0 0.004115226 0 −108
EEF1A1 0.5 1.340740741 46 916 0.004464286 144.4425679 −89
HIST3H3 0.5 1.059259259 8 28 0.003816794 9.085714286 −127
MCF2L2 0.5 1.155555556 21 0 0.004016064 0 −114
SIRT4 0.5 1.059259259 8 20 0.003816794 6.285714286 −127
MAPK14 0.5 1.155555556 21 270 0.004016064 75.87614053 −114
CN0T1 0.5 1.214814815 29 102 0.004149378 38.86666667 −106
PREPL 0.5 1.2 27 0 0.004115226 0 −108
PDCD1 0.5 1.2 27 0 0.004115226 0 −108
FOXOl 0.5 1.037037037 5 6 0.003773585 1 −130
HIST1H1B 0.5 1.037037037 5 8 0.003773585 2.566666667 −130
TAF6L 0.5 1.207407407 28 34 0.004132231 3.075757576 −107
ATG5 0.5 1.022222222 3 2 0.003745318 1 −132
KAT5 0.5 1.066666667 9 32 0.003831418 5.803174603 −126
ATXN7L2 0.5 1.2 27 0 0.004115226 0 −108
PRMT5 0.5 1.318518519 43 708 0.004405286 131.1924652 −92
DICER1 0.5 1.214814815 29 78 0.004149378 9.36469364 −106
HNF4A 0.5 1.066666667 9 28 0.003831418 6.469047619 −126
ACSS2 0.5 1.014814815 2 0 0.003731343 0 −133
DDOST 0.5 1.222222222 30 66 0.004166667 3.923840779 −105
FOX03 0.5 1.066666667 9 46 0.003831418 14.66753247 −126
TP53 0.5 1.259259259 35 852 0.004255319 247 .7405667 −100
SLC25A13 0.5 1.237037037 32 200 0.004201681 58.17817533 −103
NCOA2 0.5 1.066666667 9 28 0.003831418 5.857142857 −126
MAPK8 0.5 1.074074074 10 24 0.003846154 4.271428571 −125
RBI 0.5 1.118518519 16 122 0.003937008 27 .02950938 −119
SLC25A5 0.5 1.251851852 34 262 0.004237288 39.46214475 −101
IP09 0.5 1.214814815 29 64 0.004149378 10.93376623 −106
MEF2C 0.5 1.051851852 7 14 0.003802281 1.934199134 −128
TARBP2 0.5 1.2 27 0 0.004115226 0 −108
NCOR1 0.5 1.103703704 14 110 0.00390625 33.77150072 −121
(Continued)
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TableA1 | Continued
ID Eccentricity Radiality Node degree Stress Closeness betweenness Centroid
WRN 0.5 1.17037037 23 50 0.004048583 5.246184371 −112
SIRT6 0.5 1.059259259 8 18 0.003816794 4.004761905 −127
SUPT3H 0.5 1.207407407 28 34 0.004132231 3.075757576 −107
KIF7 0.5 1.2 27 0 0.004115226 0 −108
SLC25A6 0.5 1.266666667 36 340 0.004273504 62.29482874 −99
TADA1 0.5 1.207407407 28 34 0.004132231 3.075757576 −107
RUVBL2 0.5 1.288888889 39 500 0.004329004 92.11672012 −96
SUV39H1 0.5 1.051851852 7 18 0.003802281 5.785714286 −128
KAT2B 0.5 1.2 27 472 0.004115226 157 .352381 −108
ATXN7L3 0.5 1.2 27 0 0.004115226 0 −108
NFE2 0.5 1.02962963 4 4 0.003759398 0.7 −131
RPL38 0.5 1.222222222 30 64 0.004166667 3.657072047 −105
XRCC6 0.5 1.259259259 35 626 0.004255319 162.0582313 −100
KPNA2 0.5 1.2 27 196 0.004115226 30.50607726 −108
ACACA 0.5 1.185185185 25 120 0.004081633 29.98435813 −110
HIST4H4 0.5 1.037037037 5 8 0.003773585 2.333333333 −130
EIF2B4 0.5 1.2 27 0 0.004115226 0 −108
KPNA3 0.5 1.185185185 25 136 0.004081633 30.1805203 −110
ENY2 0.5 1.2 27 0 0.004115226 0 −108
DYNC1H1 0.5 1.222222222 30 248 0.004166667 39.60332249 −105
RARB 0.5 1.014814815 2 0 0.003731343 0 −133
HIST2H2AB 0.5 1.214814815 29 194 0.004149378 18.36998916 −106
SLC25A3 0.5 1.266666667 36 300 0.004273504 25.33091014 −99
KAT2A 0.5 1.237037037 32 246 0.004201681 72.24401154 −103
HIST1H4A 0.5 1.140740741 19 120 0.003984064 39.88333333 −116
SUPT7L 0.5 1.207407407 28 34 0.004132231 3.075757576 −107
MAP1LC3B 0.5 1.022222222 3 2 0.003745318 1 −132
RELA 0.5 1.162962963 22 282 0.004032258 72.94258519 −113
RRP8 0.5 1.022222222 3 2 0.003745318 0.4 −132
TADA2B 0.5 1.2 27 0 0.004115226 0 −108
ARNTL 0.5 1.037037037 5 4 0.003773585 1.333333333 −130
TAF9 0.5 1.259259259 35 434 0.004255319 159.8090909 −100
HSPA5 0.5 1.340740741 46 986 0.004464286 135.950784 −89
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TableA2 | Biological processes associated with interacting proteins in the Sirt 1 interaction maps with signiﬁcant p-value.
GO-ID p-Value Description Genes
6333 2.81 E−07 Chromatin assembly or disassembly HIST1H2BC|SIRT4|SIRT6|SIRT1|SIRT2|S
16763 1.39E−06 Transferase activity, transferring pentosyl SIRT4|SIRT6|SIRT1|SIRT3
16575 1.54E−06 Histone deacetylation HDAC2|SIRT1|SIRT2
6355 2.05E−06 Regulation of transcription, DNA-dependent AR|RELA|SIRT4|SIRT6|ARNTL|SIRT1|YB)
31323 2.28E−06 Regulation of cellular metabolism AR|EIF2C1|RELA|SIRT4|SIRT6|ARNTL|SI
6476 2.45E−06 Protein amino acid deacetylation HDAC2|SIRT1|SIRT2
32774 2.83E−06 RNA biosynthesis AR|RELA|SIRT4|SIRT6|ARNTL|SIRT1|YB)
17136 3.21 E−06 NAD-dependent histone deacetylase activity SIRT1|SIRT2
6259 3.67E−06 DNA metabolism HIST1H2BC|HDAC2|SIRT4|RUVBL2|SIRT
45449 4.65E−06 Regulation of transcription AR|RELA|SIRT4|SIRT6|ARNTL|SIRT1|YB)
16070 5.39E−06 RNA metabolism AR|RELA|SIRT4|SYNCRIP|SIRT6|ARNTL|
6996 6.66E−06 Organelle organization and biogenesis HIST1H2BC|HDAC2|SIRT4|RUVBL2|SIRT
6139 8.88E−06 Nucleobase, nucleoside, nucleotide and rHIST1H2BC|AR|RELA|SIRT4|SYNCRIP|SI
3950 9.44E−06 NAD+ ADP-ribosyltransferase activity SIRT4|SIRT1|SIRT3
5667 1.70E−05 Transcription factor complex EP300|HDAC2|JUN|RELA|RUVBL2
45892 1.84E−05 Negative regulation of transcription, DNA SIRT4|SIRT6|SIRT1|SIRT2|SIRT3
16570 2.87E−05 Histone modiﬁcation HDAC2|SIRT1|SIRT2
43170 4.14E−05 Macromolecule metabolism HIST1H2BC|AR|EIF2C1|RELA|SIRT4|SYN
3700 5.96E−05 Transcription factor activity AR|EP300|HDAC2|HNF4A|HSF1|JUN|REL
123 1.15E−04 Histone acetyltransferase complex EP300|RUVBL2
30528 1.86E−04 Transcription regulator activity AR|EP300|HDAC2|HNF4A|HSF1|JUN|REL
19538 3.16E−04 Protein metabolism HIST1H2BC|EIF2C1|RELA|SIRT4|RPS27L
5488 3.41 E−04 Binding EIF2C1|SYNCRIP|RPS27L|RPL38|YBX1|F
43283 3.81 E−04 Biopolymer metabolism HIST1H2BC|AR|RELA|SIRT4|SYNCRIP|SI
16932 9.70E−04 Transferase activity, transferring glycosyl SIRT4|SIRT6|SIRT1|SIRT3
6950 1.12E−03 Response to stress AR|EP300|HNF4A|HSF1|RELA|RUVBL2|S
3678 1.44E−03 DNA helicase activity RUVBL2|WRN
15320 1.82E−03 Phosphate carrier activity SLC25A3
31509 1.82E−03 Telomeric heterochromatin formation SIRT2
31509 1.82E−03 Telomeric heterochromatin formation SIRT2
183 1.82E−03 Chromatin silencing at rDNA SIRT2
35026 1.82E−03 Leading edge cell differentiation JUN
6348 1.82E−03 Chromatin silencing at telomere SIRT2
7517 2.76E−03 Muscle development EP300|SIRT1|SIRT2
8080 2.77E−03 N-acetyltransferase activity EP300|NAT10
16282 3.43E−03 Eukaryotic 43S preinitiation complex EIF2C1|RPS3
16410 3.58E−03 N-acyltransferase activity EP300|NAT10
3707 3.58E−03 Steroid hormone receptor activity AR|HNF4A
15207 3.64E−03 Adenine transporter activity SLC25A5
42903 3.64E−03 Tubulin deacetylase activity SIRT2
10224 3.64E−03 Response to UV-B RELA
4882 3.64E−03 Androgen receptor activity AR
15810 3.64E−03 Aspartate transport SLC25A13
5496 4.02E−03 Steroid binding AR|HNF4A
4879 4.02E−03 Ligand-dependent nuclear receptor activity AR|HNF4A
45137 4.02E−03 Development of primary sexual characteristics AR|SIRT1
8406 4.02E−03 Gonad development AR|SIRT1
8134 5.18E−03 Transcription factor binding EP300|HDAC2|RELA|SIRT2
40009 5.45E−03 Regulation of growth rate WRN
5345 5.45E−03 Purine transporter activity SLC25A5
4032 5.45E−03 Aldehyde reductase activity AR
48511 6.78E−03 Rhythmic process ARNTL|SIRT1
(Continued)
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TableA2 | Biological processes associated with interacting proteins in the Sirt 1 interaction maps with signiﬁcant p-value.
GO-ID p-Value Description Genes
5497 7 .26E−03 Androgen binding AR
6980 7 .26E−03 Redox signal response SIRT2
40007 8.18E−03 Growth AR|RUVBL2|WRN
15205 9.07E−03 Nucleobase transporter activity SLC25A5
42301 9.07E−03 Phosphate binding RELA
45120 9.07E−03 Pronucleus HSF1
5850 9.07E−03 Eukaryotic translation initiation factor 2 complex EIF2C1
30850 9.07E−03 Prostate gland development AR
19899 9.08E−03 Enzyme binding HDAC2|RELA|SIRT2
35267 1.09E−02 NuA4 histone acetyltransferase complex RUVBL2
35035 1.09E−02 Histone acetyltransferase binding SIRT2
45084 1.09E−02 Positive regulation of interleukin-12 biosynthesis RELA
1889 1.09E−02 Liver development RELA
42177 1.09E−02 Negative regulation of protein catabolism RELA
9887 1.10E−02 Organ morphogenesis AR|EP300|RELA|SIRT1
6310 1.11E−02 DNA recombination RUVBL2|WRN
45935 1.12E−02 Positive regulation of nucleobase, nucleoside, nucleotide aI EP300|JUN|RELA
3702 1.17E−02 RNA polymerase II transcription factor activity HNF4A|JUN|RELA
5313 1.27E−02 l-Glutamate transporter activity SLC25A13
8143 1.27E−02 Poly(A) binding SYNCRIP
43189 1.27E−02 H4/H2A histone acetyltransferase complex RUVBL2
43565 1.29E−02 Sequence-speciﬁc DNA binding AR|HNF4A|HSF1|JUN
8270 1.36E−02 Zinc ion binding AR|EP300|HNF4A|SIRT4|SIRT6|RPS
32615 1.45E−02 Interleukin-12 production RELA
15172 1.45E−02 Acidic amino acid transporter activity SLC25A13
8139 1.45E−02 Nuclear localization sequence binding KPNA3
45075 1.45E−02 Regulation of interleukin-12 biosynthesis RELA
51059 1.45E−02 NF-kappaB binding RELA
5868 1.45E−02 Cytoplasmic dynein complex DYNC1H1
8026 1.45E−02 ATP-dependent helicase activity RUVBL2|WRN
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TableA3 | Interacting protein partner of Sirt-1 involved in various pathways.
Pathways (in human) Interacting proteins in Sirt-1 interactome
E2F transcription factor network E2F1
FoxO family signaling FOX03A, FOXOl
HIF-2 alpha transcription factor Network HIF2A, ARNT
Regulation of Androgen receptor activity AR, NCOA1
Regulation of retinoblastoma protein RB1
P73 transcription factor network P300, P73
Signaling events mediated by HDAC class III P300, HISTH1B, FOX04, PGC1A, MEF2D, HDAC4,TP53, MYOD, PCAF , FHL2, BAX, XRCC6
TableA4 | Cellular localization of the Sirt-1 interacting proteins by GO studies.
GO-ID p-Value Cellular component Genes
5677 1.81E−12 Chromatin silencing complex SIRT4|SIRT6|SIRT1|SIRT2|SIRT3
44451 1.10E−09 Nucleoplasm part HDAC2|EP300|JUN|RELA|SIRT4|RUVBL2|SIRT6|SIRT
16585 5.30E−09 Chromatin remodeling complex SIRT4|SIRT6|SIRT1|SIRT2|SIRT3
5654 6.05E−09 Nucleoplasm HDAC2|EP300|JUN|RELA|SIRT4|RUVBL2|SIRT6|SIRT
44428 8.71E−08 Nuclear part HDAC2|EP300|JUN|RELA|SIRT4|SYNCRIP|RUVBL2|SI
31981 9.86E−08 Nuclear lumen HDAC2|EP300|JUN|RELA|SIRT4|RUVBL2|SIRT6|SIRT
43234 1.54E−07 Protein complex EIF2C1|RELA|SIRT4|SYNCRIP|RPS27L|SIRT6|RPL38|S
44422 1.66E−07 Organelle part SLC25A5|RELA|SIRT4|SYNCRIP|SIRT6|RPL38|SIRT1|S
44446 1.66E−07 Intracellular organelle part SLC25A5|RELA|SIRT4|SYNCRIP|SIRT6|RPL38|SIRT1|S
43233 6.77E−07 Organelle lumen HDAC2|EP300|JUN|RELA|SIRT4|RUVBL2|SIRT6|SIRT
31974 6.77E−07 Membrane-enclosed lumen HDAC2|EP300|JUN|RELA|SIRT4|RUVBL2|SIRT6|SIRT
43229 6.11E−06 Intracellular organelle SYNCRIP|RPS27L|RPL38|YBX1|RPS3|HSF1|SLC25A3|
43226 6.13E−06 Organelle SYNCRIP|RPS27L|RPL38|YBX1|RPS3|HSF1|SLC25A3|
5622 1.55E−05 Intracellular EIF2C1|SYNCRIP|RPS27L|RPL38|YBX1|RPS3|MCF2L2
44424 1.95E−05 Intracellular part EIF2C1|SYNCRIP|RPS27L|RPL38|YBX1|RPS3|HSF1|SL
5634 2.98E−05 Nucleus HISTlH2BC|AR|RELA|SIRT4|SYNCRIP|SIRT6|WRN|Af
5667 3.71E−05 Transcription factor complex HDAC2|EP300|JUN|RELA|RUVBL2
123 1.59E−04 Histone acetyltransferase complex EP300|RUVBL2
43231 2.31E−04 Intracellular membrane-bound organelle HIST1H2BC|AR|SLC25A5|RELA|SIRT4|SYNCRIP|SIRTE
43227 2.39E−04 Membrane-bound organelle HIST1H2BC|AR|SLC25A5|RELA|SIRT4|SYNCRIP|SIRTE
16282 4.74E−03 Eukaryotic 43S preinitiation complex EIF2C1|RPS3
31967 8.64E−03 Organelle envelope SLC25A13|SLC25A5|SLC25A3|KPN A3
31975 8.96E−03 Envelope SLC25A13|SLC25A5|SLC25A3|KPN A3
5743 9.48E−03 Mitochondrial inner membrane SLC25A13|SLC25A5|SLC25A3
5850 1.07E−02 Eukaryotic translation initiation factor 2 complex EIF2C1
45120 1.07E−02 Pronucleus HSF1
19866 1.13E−02 Organelle inner membrane SLC25A13|SLC25A5|SLC25A3
5830 1.15E−02 Cytosolic ribosome (sensu Eukaryota) RPL38|RPS3
35267 1.28E−02 NuA4 histone acetyltransferase complex RUVBL2
5737 1.45E−02 Cytoplasm AR|EIF2C1|SLC25A5|RELA|SYNCRIP|RPS27L|RPL38|S
43189 1.50E−02 H4/H2A histone acetyltransferase complex RUVBL2
31966 1.50E−02 Mitochondrial membrane SLC25A13|SLC25A5|SLC25A3
5868 1.71E−02 Cytoplasmic dynein complex DYNC1H1
5740 1.87E−02 Mitochondrial envelope SLC25A13|SLC25A5|SLC25A3
Excelsheetswithmorethedetailscanbefoundontheselinks.
• Complete details about the Biological processes of Sirt1 and its interacting partners as analyzed by GO studies: http://bit.ly/s0XBTz
• DetailsregardingHUBproteins,AveragepathlengthandbiologicalprocessesandcellularlocalizationassociatedwithSirtlhubnodes
at bit.ly/hubproteinsofSIRT1Network
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